NDAINJECTIONINJECTABLE
Approved
Jul 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
2/8 — Basic
Drug data last refreshed 12h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INNOHEP (tinzaparin sodium) is a low-molecular-weight heparin (LMWH) administered by subcutaneous injection for thromboembolism prevention and treatment. It works by enhancing the inhibition of clotting factors Xa and IIa, reducing thrombus formation in patients at risk of deep vein thrombosis and pulmonary embolism.
LOE Approaching
As an LMWH facing patent expiration and moderate competitive pressure (30%), the brand team is likely focused on retention strategies and line extensions rather than aggressive growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer
Started Aug 2010
900 enrolled
Venous Thromboembolism
Innohep® in Elderly Patients With Impaired Renal Function Treated for Acute Deep Vein Thrombosis
Started Dec 2005
541 enrolled
Deep Vein Thrombosis
Innohep for Prophylaxis of Venous Thromboembolism in Brain Tumor Patients
Started Feb 2004
40 enrolled
Primary Brain Tumor
Career Relevance
Positions on INNOHEP are typically focused on managing market share erosion, supporting healthcare provider relationships, and preparing for generic entry. Career growth may be limited by the product's LOE stage, making it better suited for professionals seeking stable roles or transition positions rather than rapid advancement.
Worked on INNOHEP at Leo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.